Adam B. Weiner, Urologist at Cedars Sinai Medical Center, shared a post on X:
“PRIMARY2: Can Stockholm3 outperform PSA for prostate cancer screening?
Just out in Annals of Int Med.
- ~12k pts (50–74 yrs) underwent paired PSA + Stockholm3 testing with 2-year registry follow-up.
- Compared: Stockholm3 (≥11) vs PSA ≥3 ng/mL for referral to MRI/biopsy.
- ≥GG2 PCa detection: 90% vs 74% sensitivity.
- False negatives cut by >60%: 10% vs 26%.
- Specificity nearly identical: 89% vs 90%.
Decision-curve analysis favored Stockholm3, with fewer missed significant cancers and fewer unnecessary biopsies.
Implication: Risk-adapted screening with Stockholm3 may improve early detection over PSA alone.
Caveats: Only 2-year follow-up, ~25% participation rate, predominantly European cohort, and cost-effectiveness remains to be established.”
Title: Stockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up
Authors: Thorgerdur Pálsdóttir, Chiara Micoli, Martin Eklund, Henrik Grönberg, Fredrik Jäderling, Derya Tilki, Daniel W. Lin, Matthew R. Cooperberg, Scott E. Eggener, Kevin C. Oeffinger, Tobias Nordström, Hari T. Vigneswaran.
Other articles about GU Oncology on OncoDaily.
